Beacon Therapeutics reported a Phase 3 success for laruparetigene zovaparvovec (laru-zova) in X-linked retinitis pigmentosa. The company said the treatment met its primary endpoint in the VISTA study, providing one of the clearest late-stage signals yet in gene therapy for a blinding rare inherited disease. The Phase 3 milestone also comes as investors scrutinize whether gene therapies can deliver durable benefit and commercial viability beyond earlier mixed outcomes across the modality. Beacon’s update positions its program as a potential differentiator in ophthalmic gene therapy—where measurable functional endpoints can more readily translate into real-world clinical value.